Ferozsons Laboratories Limited (PSX:FEROZ)
333.00
+4.84 (1.47%)
At close: Oct 15, 2026
Ferozsons Laboratories Revenue
In the fiscal year ending June 30, 2026, Ferozsons Laboratories had annual revenue of 23.96B PKR with 27.05% growth. Ferozsons Laboratories had revenue of 5.79B in the quarter ending June 30, 2026, with 28.42% growth. That makes Ferozsons Laboratories the 23,748th largest company in the world by revenue and 149th in Pakistan.
Revenue
23.96B
Revenue Growth
+27.05%
P/S Ratio
0.60
Revenue / Employee
14.29M
Employees
1,556
Market Cap
14.48B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 23.96B | 5.10B | 27.05% |
| Jun 30, 2025 | 18.86B | 3.00B | 18.94% |
| Jun 30, 2024 | 15.85B | 4.40B | 38.38% |
| Jun 30, 2023 | 11.46B | 2.13B | 22.80% |
| Jun 30, 2022 | 9.33B | 450.80M | 5.08% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories (Pakistan) | 77.02B |
| GlaxoSmithKline Pakistan | 67.12B |
| The Searle Company | 36.81B |
| Highnoon Laboratories | 28.50B |
| AGP Limited | 27.70B |
| Citi Pharma | 14.08B |
| Macter International | 12.17B |
| Otsuka Pakistan | 4.11B |